Abstract
Racial and ethnic minoritized groups and socioeconomically disadvantaged communities experience longstanding health-related disparities in the US and were disproportionately affected throughout the COVID-19 pandemic. How departments of public health can explicitly address these disparities and their underlying determinants remains less understood. To inform future public health responses, this paper details how California strategically placed health equity at the core of its COVID-19 reopening and response policy, known as the Blueprint for a Safer Economy. In effect from August 2020 to June 2021, “the Blueprint” employed the use of the California Healthy Places Index (HPI), a summary measure of 25 social determinants of health constructed at the census tract level, to guide activities. Using California’s approach, we categorized the state population by HPI quartiles at the state and within-county levels (HPIQ1 representing the least advantaged, HPIQ4, the most advantaged) from HPI data available to demonstrate how the state monitored COVID-19 test, case, mortality, and vaccine outcomes using equity metrics developed for the Blueprint. Notable patterns emerged. Testing disparities disappeared during the summer and winter surges but resurfaced between surges. Monthly case rate ratios (RR) peaked in May 2020 for HPIQ1 compared to HPIQ4 (RR 6.61, 95%CI: 6.41–6.81), followed by mortality RR peaking in June 2020 (RR 5.06, 95% CI: 4.34–5.91). As the pandemic wore on, case and mortality disparities between lower HPI quartiles relative to HPIQ4 reduced but remained. Utilizing an ABSM, such as HPI, enabled a data-driven approach to identify priority communities, allocate resources, and monitor outcomes based on need during a large-scale public health emergency.
Competing Interest Statement
PBS and ATK acknowledge funding from the National Foundation for the Centers for Disease Control and Prevention and the California Equitable Recovery Initiative (CERI). ATK acknowledges funding from the UCSF Division of Pulmonary and Critical Care Medicine T32 Fellowship. All other authors have no potential or actual conflicts to disclose.
Funding Statement
The authors acknowledge funding from the Centers for Disease Control and Prevention for the 'National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities' (PI: Lee/Shete Award 6 NH75OT000035-01-03). PBS and ATK acknowledge funding from the California Equitable Recovery Initiative (CERI). ATK acknowledges funding from the UCSF Division of Pulmonary and Critical Care Medicine T32 Fellowship. The funding sources had no role in the design of this study nor any role during its execution, analysis, interpretation of the data, or decision to submit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analyses conducted were considered not research from the State of California Health and Human Services Agency's Committee for the Protection of Human Subjects (Project No: 2023-218), as data and results were considered essential components of California Department of Public Health public health surveillance. This decision is issued under the California Health and Human Services Agency's Federalwide Assurance #00000681 with the Office of Human Research Protections.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Figure 1 data are available on the state of California Open Data Portal (data.ca.gov) and in the public repository with analytic code at: https://github.com/kwantify/equipca_2023_equityframework. Weekly time-series data of COVID-19 test, case, and mortality outcomes at the census tract level and of vaccine doses administered by ZIP Code are considered protected public health data. Investigators interested in accessing this data should contact the corresponding author to discuss the process for developing a data use agreement for data access.
